Idorsia Ltd (SIX: IDIA) today announces the initial findings of REACT, a Phase 3 study which investigated the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed ...
In Japan, PIVLAZ™ (clazosentan) 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid ...
ALLSCHWIL/BASEL, SWITZERLAND - 27 September 2010 - Actelion Ltd (SIX: ATLN) announced today the initial results of CONSCIOUS-2 a clinical study evaluating the safety and efficacy of clazosentan in ...
PIVLAZ was evaluated in placebo-controlled, randomized, double-blind studies in adult Japanese patients post-aSAH treated by endovascular coiling or microsurgical clipping. PIVLAZ was shown to reduce ...
Sosei Group Corporation announces that Pivlaz (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results